Home » Stocks » PRVB

Provention Bio, Inc. (PRVB)

Stock Price: $6.75 USD -0.05 (-0.74%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $6.77 +0.02 (0.30%) May 13, 5:19 PM
Market Cap 430.95M
Revenue (ttm) n/a
Net Income (ttm) -118.44M
Shares Out 62.26M
EPS (ttm) -2.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $6.75
Previous Close $6.80
Change ($) -0.05
Change (%) -0.74%
Day's Open 6.81
Day's Range 6.55 - 6.93
Day's Volume 570,371
52-Week Range 6.14 - 20.05

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

RED BANK, N.J., May 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial re...

1 week ago - PRNewsWire

RED BANK, N.J., May 3, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today anno...

1 week ago - PRNewsWire

RED BANK, N.J., April 29, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it ...

2 weeks ago - PRNewsWire

RED BANK, N.J., April 27, 2021 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the Com...

2 weeks ago - PRNewsWire

New York, New York--(Newsfile Corp. - April 21, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB). Such investo...

3 weeks ago - Newsfile Corp

Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Celcuity Inc (NASDAQ: CELC) shares are trading higher after the company announced a worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to develop and commercialize gedatolisib. Celcuity is a cel...

Other stocks mentioned: CELC
1 month ago - Benzinga

Provention Bio Inc (NASDAQ: PRVB) revealed it had received a notification on April 2 from the FDA stating that the agency has identified deficiencies that preclude discussion of labeling and post-market...

1 month ago - Benzinga

RED BANK, N.J., April 8, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the ...

1 month ago - PRNewsWire

Provention Bio (PRVB) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

1 month ago - Zacks Investment Research

RED BANK, N.J., March 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that mana...

2 months ago - PRNewsWire

Provention Bio Inc (NASDAQ: PRVB) is making its way into China with a new deal with a subsidiary of Huadong Medicine to work on PRV-3279, a bispecific antibody-based molecule targeting CD32B and CD79B, ...

2 months ago - Benzinga

RED BANK, N.J., Feb. 18, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it w...

2 months ago - PRNewsWire

RED BANK, N.J., Feb. 17, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, and Hangzhou Zhongmei Hu...

2 months ago - PRNewsWire

These drugmakers could double your money this year.

Other stocks mentioned: BIIB
3 months ago - The Motley Fool

BILTHOVEN, Netherlands, Jan. 19, 2021 /PRNewswire/ -- Intravacc, a world leader in translational research and development of vaccines, today announced that a candidate polyvalent inactivated coxsackievi...

3 months ago - PRNewsWire

RED BANK, N.J., Jan. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pric...

3 months ago - PRNewsWire

RED BANK, N.J., Jan. 12, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it ...

4 months ago - PRNewsWire

Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Provention Bio is focused on slowing down, or actually preventing in some cases, the onset of autoimmune conditions. Provention's first therapeutic, teplizumab, looks set for approval in mid-2021 in wha...

4 months ago - Seeking Alpha

RED BANK, N.J., Jan. 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that manag...

4 months ago - PRNewsWire

RED BANK, N.J., Jan. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the B...

4 months ago - PRNewsWire

RED BANK, N.J., Dec. 21, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it h...

4 months ago - PRNewsWire

RED BANK, N.J., Dec. 15, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initi...

4 months ago - PRNewsWire

RED BANK, N.J., Nov. 11, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that managemen...

6 months ago - PRNewsWire

Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

RED BANK, N.J., Nov. 5, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today reported financial result...

6 months ago - PRNewsWire

Provention is leading a set of new drugs that protect beta cell functions, enabling endogenous insulin production in type 1 diabetes patients. The stock may have a PDUFA late next year; rolling BLA subm...

6 months ago - Seeking Alpha

RED BANK, N.J., Nov. 2, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced the completion ...

6 months ago - PRNewsWire

RED BANK, N.J., Oct. 29, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that it will r...

6 months ago - PRNewsWire

RED BANK, N.J., Oct. 1, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, yesterday launched a national ef...

7 months ago - PRNewsWire

RED BANK, N.J., Sept. 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the subm...

7 months ago - PRNewsWire

Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

RED BANK, N.J., Sept. 8, 2020 /PRNewswire/ -- Provention Bio, Inc.

8 months ago - PRNewsWire

OLDWICK, N.J., Aug. 31, 2020 /PRNewswire/ -- Provention Bio, Inc.

8 months ago - PRNewsWire

Under looked biotech company might be near tipping point

8 months ago - The Dog of Wall Street

Each of these companies has the potential to generate life-changing returns.

Other stocks mentioned: VRTX
9 months ago - The Motley Fool

OLDWICK, N.J., Aug. 11, 2020 /PRNewswire/ -- Provention Bio, Inc.

9 months ago - PRNewsWire

Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

OLDWICK, N.J., Aug. 6, 2020 /PRNewswire/ -- Provention Bio, Inc.

9 months ago - PRNewsWire

Provention Bio: Undervalued And Overlooked Biotech Company - Diabetes Is Not Going Away Anytime Soon

9 months ago - Seeking Alpha

Provention Bio is developing a drug that could delay the onset of diabetes, and if it's successful, the company's stock could soar.

10 months ago - The Motley Fool

OLDWICK, N.J., June 30, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today a change...

10 months ago - PRNewsWire

OLDWICK, N.J., June 22, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the clos...

10 months ago - PRNewsWire

OLDWICK, N.J., June 17, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pric...

10 months ago - PRNewsWire

The company announced a public offering of common stock.

10 months ago - The Motley Fool

OLDWICK, N.J., June 16, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it ...

10 months ago - PRNewsWire

Provention Bio (PRVB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

The company released positive data from a clinical trial for one of its pipeline candidates.

10 months ago - The Motley Fool

The company released positive data from a clinical trial for one of its pipeline candidates.

10 months ago - The Motley Fool

About PRVB

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treat... [Read more...]

Industry
Biotechnology
CEO
Ashleigh Palmer
Employees
59
Stock Exchange
NASDAQ
Ticker Symbol
PRVB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Provention Bio stock is "Strong Buy." The 12-month stock price forecast is 18.21, which is an increase of 169.78% from the latest price.

Price Target
$18.21
(169.78% upside)
Analyst Consensus: Strong Buy